论文部分内容阅读
目的观察伊立替康联合顺铂治疗小细胞肺癌(SCLC)的近期疗效及毒副反应。方法伊立替康200mg/m2加入生理盐水250ml中静脉滴注60min,第1天;顺铂25mg/m2加入生理盐水40ml中静脉推注,第1～3天。21天为1周期,2周期后评价疗效。结果可评价疗效20例,其中PR13例,NC4例,PD3例,总缓解率65%,主要毒副反应为腹泻、骨髓抑制、恶心、呕吐。结论伊立替康联合顺铂治疗小细胞肺癌有明显的疗效,毒副反应可以耐受,可以作为小细胞肺癌的临床治疗的有效方案之一。
Objective To observe the short-term curative effect and toxicity of irinotecan combined with cisplatin in the treatment of small cell lung cancer (SCLC). Methods Irinotecan 200mg / m2 was added to normal saline 250ml intravenously for 60min, on the first day; cisplatin 25mg / m2 added normal saline 40ml intravenous injection, the first to 3 days. 21 days for 1 cycle, 2 cycles after the evaluation of efficacy. The results can be evaluated in 20 cases, of which PR13 cases, NC4 cases, PD3 cases, the overall response rate was 65%, the main side effects of diarrhea, bone marrow suppression, nausea and vomiting. Conclusion Irinotecan combined with cisplatin in the treatment of small cell lung cancer has obvious curative effect and toxic side effects can be tolerated. It can be used as an effective treatment for small cell lung cancer.